Navigation Links
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
Date:8/11/2008

involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release pu
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
10. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Hologic, Inc. (NASDAQ: HOLX ) ... financial results for the third quarter of fiscal 2015 ... In conjunction with the release, management will host a ... Interested participants may listen to the call ... ) or 719-325-4804 (for international callers) and referencing ...
(Date:7/6/2015)... FARMINGTON, Conn. , July 6, 2015 ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... E warrants to purchase 21,917,808 shares of its ... 2,191,781 shares of its common stock.  Certain funds ...
(Date:7/6/2015)... July 6, 2015  Impax Laboratories, Inc. (NASDAQ: ... Ph.D. has resigned from the Company,s Board of Directors ... was a co-founder of Impax in 1995 and served ... October 2006 until April 2014. Logo - ... Impax,s President and Chief Executive Officer stated, "We wish ...
Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5
... , , ... schedule of events at the Cardiovascular Research Foundation,s (CRF) annual ... 21st to Friday, September 25th, in San Francisco, CA. at ... world,s largest events for those performing cardiac diagnostics and interventions. ...
... 11 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ... destroying breast cancer cells, using stem cell technology. , ... us to identify the protein expression in the original ... ability to identify the molecular markers of these cells ...
Cached Medicine Technology:InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundation's (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting 2New stem cell identification technology could cure breast cancer 2
(Date:7/6/2015)... ... July 06, 2015 , ... World renowned Los ... to achieve their ideal appearance through comprehensive treatment solutions. Individuals that want to make ... doctor and receive a plan that resolves each of their needs. , "Anytime ...
(Date:7/6/2015)... VA (PRWEB) , ... July 06, 2015 , ... ... that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® REmind® ... Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 posterior ...
(Date:7/6/2015)... ... 2015 , ... The Path of Least Resistance: The Evolution of Capitalism and ... U.S. economy over the past 40 years. The book explores the evolution of the ... book is a time capsule that chronicles the economic development of the United States ...
(Date:7/5/2015)... ... , ... Women's Excellence in Wellness, powered by Movestrong announces parent/child ... geared towards families that want their children to stay active as well as spend ... will take place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. Women’s Excellence in Wellness, ...
(Date:7/5/2015)... (PRWEB) , ... July 05, 2015 , ... Doctors at ... a new IMRT/surgery combination may one day change the outlook for people with pleural ... it now. , Researchers report that five mesothelioma patients treated with 25Gy ...
Breaking Medicine News(10 mins):Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:New Book Brings Reveals The Repercussions Associated With The Global Economy 2Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2
... Modest reduction may be worthwhile for those most at ... News) -- Children who are predisposed to recurrent urinary ... a new Australian study suggests that such prophylactic therapy ... Only 13 percent of youngsters who were given the ...
... ... State Long Term Care Ombudsman, Speaks at Gladys B. Jacobs Manor, in North Central ... Philadelphia, ... Term Care Ombudsman, the first Latina ever appointed to that position, recently spoke at ...
... In response to rising suicide and divorce rates within ... marriages and families, will present its Weekend to Remember® ... in Vancouver, Wash. from Nov. 6 - 8 at the ... Ore. from Nov. 20 - 22 at the Red Lion ...
... JACKSONVILLE, Fla., Oct. 28 Blue Cross and Blue Shield ... Echo Gold Award for the Power of the ... from worldwide companies, the competition honors the best direct marketing ... presented at the 2009 international awards ceremony in San Diego ...
... Oct. 28 If we get a boo-boo, we might know ... mom kiss it and make it all better. But, what ... of us who aren,t prepared for dental emergencies can quickly get ... Drug Company at: , http://inr.mediaseed.tv/oneClip_C/?feed=Ss8P5Rb1iQulYDAELUR0M_kpwKp_6YSM , ...
... voice on the telephone line when you fear you,ve had ... questions about the H1N1 flu pandemic. , The nation,s 60 ... to H1N1, with states putting their poison centers to work ... Florida,s three poison control centers have been assisting the ...
Cached Medicine News:Health News:Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 2Health News:Preventive Antibiotics Help Some Kids Fend Off Urinary Infections 3Health News:Head of PA Department of Aging Speaks at the Richard Allen Committee's 17th Annual Senior Citizen's Event 2Health News:FamilyLife Supports Military Marriages in Portland Area 2Health News:Blue Cross and Blue Shield of Florida's Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 2Health News:American Association of Poison Control Centers: Count U.S. Poison Centers Among First Responders in H1N1 Flu Pandemic 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: